Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient's individual tumour-specific mutations. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4(+) T cells. Vaccination with such CD4(+) immunogenic mutations confers strong antitumour activity. Encouraged by these findings, we established a process by which mutations identified by exome sequencing could be selected as vaccine targets solely through bioinformatic prioritization on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding capacity for rapid production as synthetic poly-neo-epitope messenger RNA vaccines. We show that vaccination with such polytope mRNA vaccines induces potent tumour control and complete rejection of established aggressively growing tumours in mice. Moreover, we demonstrate that CD4(+) T cell neo-epitope vaccination reshapes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent immunodominant antigen in mice, indicating orchestration of antigen spread. Finally, we demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers as well by employing the same predictive algorithm on corresponding human cancer types. Thus, the tailored immunotherapy approach introduced here may be regarded as a universally applicable blueprint for comprehensive exploitation of the substantial neo-epitope target repertoire of cancers, enabling the effective targeting of every patient's tumour with vaccines produced 'just in time'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, peptide-based immunotherapeutics often tend to induce primarily CD4+ T-cell responses [36].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutated epitopes of Pbk and Actn4 were recognized and reacted to by CD8+ or CD4+ T cells, respectively, upon RNA monotope vaccinations and showed good MHC class I binding scores (‘low score’ 0.1 and 0.2, respectively) (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Additional neoatigens formulated in the mRNA vaccine may help improve the anti-tumor response of mRNA vaccines using neoantigens, such as demonstrated by Kreiter et al. (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
In the citing paper
“Interestingly, we also observed an elevated percentage of ChAT–GFP+ cells among CD4+ T cells carrying natural TCRs (TCR Vβ5–) (Fig. 4j,k), suggesting that ChAT expression in T cells can also be induced through ‘antigen spreading’35.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Cited by
Items 601–700 of 1,001
Peng, H. C., Li, L., Zuo, C., Chen, M. Y., Zhang, X., Myers, N. B., Hogg, G. D., DeNardo, D. G., Goedegebuure, S. P., Hawkins, W. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1039226 · Cited by 25
“Of note, neoantigen-specific CD4 T cells have been identified in several neoantigen vaccine studies (9, 35) including our own neoantigen DNA vaccine trial in TNBC (38).”
BackgroundPifferi, C., Aguinagalde, L., Ruiz‐de‐Angulo, A., Sacristán, N., Baschirotto, P. T., Poveda, A. M., Jiménez‐Barbero, J., Anguíta, J., & Fernández‐Tejada, A. (2023) · Chemical Science · doi:10.1039/d2sc05639a · Cited by 25
Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma
Yang, S., Weng, M., Liang, J., Chiou, L., Hsu, Y.-C., Lee, Y.-T., Liu, S.-Y., Wu, M.-C., Chou, H.-C., Wang, L., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216192 · Cited by 28
Dillman, R. O., Nistor, G. I., & Keirstead, H. S. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2198467 · Cited by 28
Carrier-Free Nanovaccine: An Innovative Strategy for Ultrahigh Melanoma Neoantigen Loading
Zeng, T., Zang, W., Xiao, H., Jiang, Y., Lin, S., Wang, M., Li, S., Li, L., Li, C., Lü, C., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c04887 · Cited by 26
Shi, L. D., Yang, J., Nie, Y., Huang, Y., & Gu, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301261 · Cited by 28
Recent advances in neoantigen vaccines for treating non‐small cell lung cancer
Su, S., Chen, F., Xu, M., Liu, B., & Wang, L. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15126 · Cited by 29
“26 Based on clinical trials conducted in July 2017, the US and German teams confirmed the remarkable efficacy of personalized neoantigen vaccines targeting tumor mutations in treating malignant melanoma.”
Langenau, D. M., Sweet-Cordero, A., Wechsler‐Reya, R. J., & Dyer, M. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1308 · Cited by 28
Ling, L., Ruiyi, L., Wang, G., Gu, Z., & Li, Z. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.01.082 · Cited by 25
Zhang, Y., Lin, Z., Wan, Y., Cai, H., Deng, L., & Li, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02472 · Cited by 25
“In contrast with RNA and longpeptide neoantigen vaccines in preclinical and early phase clinical studies showing that immune responses were predominantly of CD4 T cells (7, 8), DTT fusion strategy significantly enhanced immunogenicity of neoantigens as well as the CTL responses.”
BackgroundMethodResultInfluentialStringhini, M., Probst, P., & Neri, D. (2020) · European Journal of Immunology · doi:10.1002/eji.201948433 · Cited by 25
Immunogenomics in personalized cancer treatments
Kiyotani, K., Toyoshima, Y., & Nakamura, Y. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00950-w · Cited by 26
The Role of Neoantigens in Cancer Immunotherapy
Zhu, Y., & Liu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682325 · Cited by 36
“The prioritization of candidate neoantigens can be achieved by the predicted binding affinities alone or in combination with the mutant expression level (50).”
BackgroundControlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors
Wijfjes, Z., van Dalen, F. J., Gall, C. M. L., & Verdoes, M. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00330 · Cited by 27
Cancer immunotherapy: exploiting neoepitopes
Platten, M., & Offringa, R. (2015) · Cell Research · doi:10.1038/cr.2015.66 · Cited by 24
New trends in antitumor vaccines in melanoma
Vásquez, M., Tenesaca, S., & Berraondo, P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.09.09 · Cited by 30
“Systemic administration of naked RNA or a nanoparticle RNA vaccine expressing tumor neoantigens has shown promising efficacy in melanoma mice models (30,31).”
BackgroundBarroso‐Sousa, R., & Ott, P. A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0738-2 · Cited by 25
Pasetto, A., & Lu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689091 · Cited by 25
“Most approaches are based on empirical testing where the T cell activation status is evaluated after co-culture with the candidate antigens (15, 16, 64).”
BackgroundTaylor, H. B., Klaeger, S., Clauser, K. R., Sarkizova, S., Weingarten-Gabbay, S., Graham, D. B., Carr, S. A., & Abelin, J. G. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100116 · Cited by 26
He, X., Zhou, S., Dolan, M., Shi, Y., Wang, J., Quinn, B., Jahagirdar, D., Huang, W., Tsuji, M., Пили, Р., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003101 · Cited by 26
“20 Thus, while targeting CD4 + T-cell epitopes via long immunogens is a dominant strategy that provides help for CD8 + T-cell generation, 21 it confounds direct induction of Ag-specific CD8 + T cells to lyse tumor cells from a pool of neoepitope candidates selected on the basis of MHC-I binding.”
Charoenkwan, P., Pipattanaboon, C., Nantasenamat, C., Hasan, M. M., Moni, M. A., Lió, P., & Shoombuatong, W. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106368 · Cited by 24
DNA based neoepitope vaccination induces tumor control in syngeneic mouse models
Viborg, N., Pavlidis, M. A., Barrio-Calvo, M., Friis, S., Trolle, T., Sørensen, A. B., Thygesen, C. B., Kofoed, S. V., Kleine‐Kohlbrecher, D., Hadrup, S. R., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00671-5 · Cited by 25
Chiang, M.-R., Shen, W.-T., Huang, P.-X., Wang, K.-L., Weng, W.-H., Chang, C.-W., Chiang, W.-H., Liu, Y.-C., Chang, S.-J., & Hu, S.-H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.033 · Cited by 23
Li, B., Jing, P., Zheng, G., Pi, C., Zhang, L., Yin, Z., Xu, L., Qiu, J., Gu, H., Qiu, T., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01644-9 · Cited by 25
“17 Considering it is necessary to ensure that the neoantigen can successfully go past all the presenting steps, the pipelines of neoantigen prediction should contain the comprehensive steps of presenting processes to generate suitable MHC-I and MHC-II neoantigen targets for preclinical experiments.”
BackgroundInfluentialLi, M., Jiang, A., Han, H., Chen, M., Wang, B., Cheng, Y., Zhang, H., Wang, X., Dai, W., Yang, W., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c03352 · Cited by 26
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma
Nielsen, J. S., Chang, A., Wick, D. A., Sedgwick, C. G., Zong, Z., Mungall, A. J. J., Martin, S. D., Kinloch, N. N., Ott-Langer, S., Brumme, Z. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1321184 · Cited by 25
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
Liu, W. R., & Shipp, M. A. (2017) · Hematology · doi:10.1182/asheducation-2017.1.310 · Cited by 28
Jiang, D., Xi, B., Tan, W., Chen, Z., Wei, J., Hu, M., Lu, X., Chen, D., Cai, H., & Du, H. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae547 · Cited by 23
“HLA-II-restricted neoantigens have been proven crucial for some antitumor responses (Kreiter et al. 2015, Khodadoust et al. 2017).”
BackgroundAutophagosomes coated in situ with nanodots act as personalized cancer vaccines
Huang, W., You, W., Zhu, Y.-Q., Gao, F., Wu, Z., Chen, G., Xiao, J., Shao, Q., Wang, L., Nie, X., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01826-8 · Cited by 24
“The categories of the neoantigens were based on the published literature 44,45 .”
Progress in cancer vaccines enabled by nanotechnology
Kim, B., Abdelfattah, N. S., Hostetler, A., & Irvine, D. J. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02021-z · Cited by 24
Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma
Kong, X., Zheng, Z., Song, G., Zhang, Z., Liu, H., Kang, J., Sun, G., Sun, G., Huang, T., Li, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876048 · Cited by 24
“Alternatively, initial drug resistance exists before exposure, preventing the drug from blocking tumor progression (6).”
BackgroundJiang, M., Fiering, S., & Shao, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1153066 · Cited by 23
Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens
Kamigaki, T., Takimoto, R., Okada, S., Ibe, H., Oguma, E., & Goto, S. (2024) · Anticancer Research · doi:10.21873/anticanres.17196 · Cited by 28
“However, CD4+ T cells also play an important role in anti-tumor immunity as they assist in the initial stimulation and maintenance of CD8+ T cell responses (18), and CD4+ T cell responses have been shown to be essential for neoantigen-related tumor regression (19).”
Hulett, T. W., Jensen, S. M., Wilmarth, P. A., Reddy, A. P., Ballesteros‐Merino, C., Afentoulis, M. E., Dubay, C., David, L. L., & Fox, B. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0331-0 · Cited by 24
“Mutation site candidates identified from our sequencing were compared to a list of heterozygous nonsynonymous protein coding 4T1 SNVs identified in prior publications [27, 28].”
BackgroundMethodInfluentialYang, P., Song, H., Feng, Z., Wang, C., Huang, P., Zhang, C., Kong, D., & Wang, W. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900010 · Cited by 25
Ashford, P., Pang, C., Moya‐García, A. A., Adeyelu, T. T., & Orengo, C. A. (2019) · Scientific Reports · doi:10.1038/s41598-018-36401-4 · Cited by 23
“We used neutral mutations (polymorphisms) from UniProt as a non-cancer control, resulting in 8 MutFams, with half of these belonging to Class II Major Histo-compatibility Antigens, for which a pool of variant alleles is likely to be advantageous 47 .”
MethodJiménez-Chávez, Á. D. J., Moreno‐Fierros, L., & Bustos‐Jaimes, I. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.09.068 · Cited by 23
Combination therapies utilizing neoepitope-targeted vaccines
Lee, K. L., Schlom, J., & Hamilton, D. H. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02729-y · Cited by 23
Booty, M. G., Hlavaty, K. A., Stockmann, A. P., Ozay, E. I., Smith, C. K., Tian, L., How, E., Subramanya, D., Venkitaraman, A., Yee, C., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100656 · Cited by 24
Zhong, X., Li, C., Zhao, G., Li, M., Chen, S., Cao, Y., Wang, Q., Sun, J., Zhu, S., & Chang, S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01682-5 · Cited by 23
Informatics for cancer immunotherapy
Hammerbacher, J., & Snyder, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx682 · Cited by 24
“One surprising finding from the analysis of the first neoantigen vaccine responses was that class II epitopes are important for vaccine effectiveness even when vaccine epitopes are predicted based on MHC I prediction algorithms [325, 326].”
BackgroundSun, C., Nagaoka, K., Kobayashi, Y., Nakagawa, H., Kakimi, K., & Nakajima, J. (2021) · Cancers · doi:10.3390/cancers13215508 · Cited by 22
Boosting Antitumor Immunity with an Expanded Neoepitope Landscape
Nagel, R., Pataskar, A., Champagne, J., & Agami, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1525 · Cited by 26
“It has to be noted, however, that mutated BRAF leads to diminished HLA class I–mediated antigen presentation, and intracellular peptides are normally not presented via the route of HLA class II, which possibly limits the clinical applicability of these findings (44, 45).”
BackgroundBakhtiarvand, V. K., Akbari, K. R.-A., Jalali, S. A., Hojjat‐Farsangi, M., Jeddi‐Tehrani, M., Shokri, F., & Shabani, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109470 · Cited by 22
mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
Xu, Z., & Fisher, D. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155728 · Cited by 29
“developed an mRNA vaccine, which harbors multiple MHC class I/II-restricted neoepitopes sequenced from B16F10 cells (49).”
BackgroundChemotherapy-Induced Neoantigen Nanovaccines Enhance Checkpoint Blockade Cancer Immunotherapy
Chen, G., Li, X., Li, R. S., Wu, K., Lei, Z., Dai, R., Roche, K. C., Wang, A. Z., & Min, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c03274 · Cited by 25
DNA vaccines as promising immuno-therapeutics against cancer: a new insight
Shariati, A., Khezrpour, A., Shariati, F. S., Afkhami, H., Yarahmadi, A., Alavimanesh, S., Kamrani, S., Modarressi, M. H., & Khani, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1498431 · Cited by 26
In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology
Mao, C., Gorbet, M.-J., Singh, A., Ranjan, A., & Fiering, S. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1810333 · Cited by 22
Ellingsen, E. B., Bounova, G., Kerzeli, I. K., Anzar, I., Simnica, D., Aamdal, E., Guren, T. K., Clancy, T., Mezheyeuski, A., Inderberg, E. M., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03624-z · Cited by 27
Nrf2 Deficiency Promotes Melanoma Growth and Lung Metastasis
Zhu, H., Jia, Z., Trush, M. A., & Li, Y. R. (2016) · doi:10.20455/ros.2016.853 · Cited by 22
“In this regard, intravenous inoculation of B16-F10 cells is a commonly used approach to creating lung metastasis in C57BL/6 mice [15–18].”
BackgroundMethodBhojnagarwala, P. S., Perales‐Puchalt, A., Cooch, N. S., Sardesai, N. Y., & Weiner, D. B. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.04.005 · Cited by 22
“Interestingly, these initial vaccines generated mainly MHC class II-driven CD4 T cell responses despite the epitopes being selected in silico for high binding affinity to MHC class I.(4,5,7) While CD4 T cells have been shown to recognize neoantigens in tumors, CD8 T cells are the main driver of neoantigen-based tumor…”
BackgroundImproving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease
Riederer, S., del Canizo, A., Navas, J., Peter, M. G., Link, E. K., Sutter, G., & Rojas, J. J. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00610-5 · Cited by 21
“In addition, reactivity against the tumor neoepitope B16-M30 [32] was also increased, although the difference was not significant.”
BackgroundSending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment
Ramirez, F., Zambrano, A., Hennis, R., Holland, N. A., Lakshmanaswamy, R., & Chacon, J. A. (2023) · Vaccines · doi:10.3390/vaccines11091465 · Cited by 23
“For example, a study by Kreiter et al. demonstrated that neoantigen-based mRNA vaccines counteracted the immunosuppressive aspect of the TIM, ultimately resulting in efficient tumor control in vivo [24].”
Jiang, C. Y., Zhao, L., Green, M. D., Ravishankar, S., Towlerton, A. M. H., Scott, A. J., Raghavan, M., Cusick, M. F., Warren, E. H., & Ramnath, N. (2024) · Scientific Reports · doi:10.1038/s41598-023-48546-y · Cited by 23
Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy
Kumari, K., Singh, A., Chaudhary, A., Singh, R. K., Shanker, A., Kumar, V., & Haque, R. (2024) · Vaccines · doi:10.3390/vaccines12050498 · Cited by 27
“These alterations can lead to impaired processing and presentation of NeoAgs, resulting in a reduction in T-cell recognition and impaired tumor elimination [83,84].”
BackgroundBioactive mesoporous silica materials-assisted cancer immunotherapy
Liu, J., Liu, J., Wang, Y., Chen, F., He, Y., Xie, X., Zhong, Y., & Yang, C. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122919 · Cited by 25
Tang, L., Huang, K., Xie, J., Yu, D., Sun, L., Huang, Q., & Bi, Y. (2017) · Aquaculture Nutrition · doi:10.1111/anu.12468 · Cited by 23
Necroptotic extracellular vesicles – present and future
Raden, Y., Shlomovitz, I., & Gerlic, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.08.011 · Cited by 21
Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories
Mizuno, S., Yamaguchi, R., Hasegawa, T., Hayashi, S., Fujita, M., Zhang, F., Koh, Y., Lee, S.-Y., Yoon, S., Shimizu, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95287-x · Cited by 23
Design and Evaluation of Synthetic Delivery Formulations for Peptide-Based Cancer Vaccines
Song, K., & Pun, S. H. (2024) · BME Frontiers · doi:10.34133/bmef.0038 · Cited by 20
“The Sahin group used NGS to identify mutations in the B16F10, CT26 and 4T1 tumors and demonstrated tumor control with immunization of some synthetic 27-mer peptides, including B16-M30 [117].”
MethodAn antigen-capturing and lymph node-targeting nanoparticle for cancer immunotherapy
Zhang, Z., Chen, X., Gong, N., Qing, G., Zhang, Y., Shi, Y., Brenner, J. S., Li, F., Xu, F., & Liang, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.087 · Cited by 20
Advances in personalized neoantigen vaccines for cancer immunotherapy
Sun, C., & Xu, S. (2020) · BioScience Trends · doi:10.5582/bst.2020.03267 · Cited by 23
“However, there is mounting evidence of the promising efficacy of class II-specific neoantigens in cancer immunotherapies (24,25).”
BackgroundYu, G., He, X., Li, X., & Wu, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113464 · Cited by 22
Interaction of glioma-associated microglia/macrophages and anti-PD1 immunotherapy
Wang, C., Chen, Q., Chen, M., Guo, S., Hou, P. K., Zou, Y., Wang, J., He, B., Zhang, Q., Chen, L., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03358-3 · Cited by 21
“Accumulating evidence indicates the importance of CD4+ T cells in tumor immunotherapy [26, 38, 39].”
BackgroundInsight into Cancer Immunity: MHCs, Immune Cells and Commensal Microbiota
Wen, M., Li, Y., Qin, X., Qin, B., & Wang, Q. A. (2023) · Cells · doi:10.3390/cells12141882 · Cited by 21
Srivastava, P. K. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176740 · Cited by 20
“33, 34; Table 2).”
Szymura, S. J., Wang, L., Zhang, T., Cha, S.-C., Song, J. Y., Dong, Z., Anderson, A., Oh, E., Lee, V., Wang, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50880-2 · Cited by 22
Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening
Zhang, J., Shen, L., & Johnston, S. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-35673-0 · Cited by 20
Cancer research in the era of immunogenomics
Wolf, Y., & Samuels, Y. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000475 · Cited by 22
“Various vaccine systems have been suggested and tested for neoantigen delivery.(121) 122 However, the most suitable vaccine format, including how to choose which neoantigens to target and how many neoantigens need to be included in the vaccine regimen, is yet to be determined.”
BackgroundLopes, A., Feola, S., Ligot, S., Fusciello, M., Vandermeulen, G., Véronique Préat, A., & Cerullo, V. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0644-7 · Cited by 21
“Indeed, immune recognition of mutation-derived epitopes seems to be mostly driven by CD4 + T cells [12, 13].”
BackgroundResultInfluentialChen, A. C., Xu, R.-H., Wang, T., Wei, J.-P., Yang, X., Liu, C.-X., Lei, G., Lyerly, H. K., Heiland, T., & Hartman, Z. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000258 · Cited by 21
Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms
Chen, J., Zhang, H., Zhou, L., Hu, Y., Li, M., He, Y., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.584367 · Cited by 21
“First, most tumors lack the expression of MHC-II molecules (68).”
BackgroundShibata, H., Xu, N., Saito, S., Zhou, L., Ozgenc, I., Webb, J., Fu, C., Zolkind, P., Egloff, A. M., & Uppaluri, R. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1958589 · Cited by 21
“These findings are also consistent with recent findings regarding the critical role of CD4 T cell help in therapeutic cancer immunity.(6,18,29,30) Considering that conventional type 1 dendritic cells (cDC1s) process SLPs and present epitopes to activate both CD8 and CD4 T cells,(5,31) vaccine platforms that encode bot…”
ResultChurch, C. D., Pulliam, T., Longino, N. V., Park, S. Y., Smythe, K. S., Makarov, V., Riaz, N., Jing, L., Amezquita, R. A., Campbell, J. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005328 · Cited by 20
Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment
Katsnelson, A. (2016) · Nature Medicine · doi:10.1038/nm0216-122 · Cited by 20
Targeting the “undruggable” RAS with biologics
Whaby, M., Khan, I., & O’Bryan, J. P. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.006 · Cited by 24
Borden, E. S., Ghafoor, S., Buetow, K. H., LaFleur, B., Wilson, M. A., & Hastings, K. T. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100700 · Cited by 22
Ren, H., Li, J., Zhang, J., Liu, J., Yang, X., Zhang, N., Qiu, Q., Li, D., Yu, Y., Liu, X., et al. (2023) · Small · doi:10.1002/smll.202302756 · Cited by 25
Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
Yao, S., Han, Y., Yang, M., Jin, K., & Lan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292861 · Cited by 21
“Speci fi cally, the presence of natural neoantigens at the top of immune checkpoints can enhance the effectiveness of signi fi cant inhibitors (171, 172).”
BackgroundKirk, A. M., Crawford, J. C., Chou, C., Guy, C. S., Pandey, K., Kozlik, T., Shah, R. K., Chung, S., Nguyen, P., Zhang, X., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101469 · Cited by 23
Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans
Fritsch, E. F., & Ott, P. A. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0565 · Cited by 19
Ma, S., Hu, K., Xue, J., Wu, D., Chu, Y., Jin, F., Zhao, W., Hu, Y., Yan, J., Wu, J., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.154663 · Cited by 19
Neoantigen sequestrated autophagosomes as therapeutic cancer vaccines
Zhang, J., Cao, J., Wang, L., Li, S., Meng, F., Liang, X., Jiang, H., Luo, R., Zhu, D., Zhang, F., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.019 · Cited by 20
Ye, L., Ma, S., Robinson, B. W. S., & Creaney, J. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1563488 · Cited by 20
T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins
Xu, Y., Salazar, G. T., Zhang, N., & An, Z. (2019) · Antibody Therapeutics · doi:10.1093/abt/tbz001 · Cited by 22
“Mutant MHC-II epitopes were also reported to drive therapeutic immune responses to cancer [52].”
BackgroundCosta-Nunes, C., Cachot, A., Bobisse, S., Arnaud, M., Genolet, R., Baumgaertner, P., Speiser, D. E., Alves, P. M. S., Sandoval, F., Adotévi, O., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1356 · Cited by 19
Clinical Data on Immunotherapy in Breast Cancer
Radosa, J. C., Stotz, L., Müller, C., Kaya, A. C., Solomayer, E., & Radosa, M. P. (2020) · Breast Care · doi:10.1159/000511788 · Cited by 20
Castro, A., Zanetti, M., & Carter, H. K. (2021) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-092820-112713 · Cited by 20
HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade
Shao, X., Huang, J. C., Niknafs, N., Balan, A., Cherry, C., White, J. R., Velculescu, V. E., Anagnostou, V., & Karchin, R. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.03.013 · Cited by 21
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy
Margolis, N., Markovits, E., & Markel, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.005 · Cited by 20
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Kilian, M., Friedrich, M., Sanghvi, K., Green, E., Pusch, S., Kawauchi, D., Löwer, M., Sonner, J. K., Krämer, C., Zaman, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1881 · Cited by 18
“Moreover, evidence of de novo MHCIrestrictedT-cell responses uponMHCII-restricted peptide vaccination exist, (34), suggesting stromal MHCII expression as prerequisite for MHCII-restricted T-cell therapy to be effective.”
BackgroundSelf-citationGeometric deep learning improves generalizability of MHC-bound peptide predictions
(2024) · doi:10.1038/s42003-024-07292-1 · Cited by 18
“While our study is on pMHC-I, our StrB methods are directly applicable to pMHC-II complexes, which play a pivotal role in cancer immunotherapy responses 59,60 but their BA is challenging to predict.”
Mirza, S., Bhadresha, K. P., Jameel, M., McCabe, M., Shahbazi, R., Ruff, P., & Penny, C. B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023565 · Cited by 18
Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy
D’Alise, A. M., & Scarselli, E. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000923 · Cited by 19
“Vaccination with synthetic mRNA vaccine encoding five selected neoantigens has also been shown to have antitumor activity in both in B16F10 melanoma and CT26 colon cancer models [14].”
BackgroundYang, Y., Meng, W., & Wang, Z. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2804069 · Cited by 20
“It is reported that mutational burden of MSI-H/dMMR CRC is nearly 20-fold higher than that of MSS/pMMR CRCs, enabling them to trigger a more robust host antitumor immune response [55–57].”
BackgroundJing, N., Wang, L., Zhuang, H., Jiang, G., & Liu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1195075 · Cited by 18
“Short peptides or RNAs targeting tumor neoantigens have proven to be more effective in mouse models (6, 7).”
BackgroundCytotoxic CD4 T cells in the mucosa and in cancer
Venkatesh, H., Tracy, S. I., & Farrar, M. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1233261 · Cited by 20
“effector function of anti-tumor CD8 T cells (116, 117).”
BackgroundRelevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies
Aparicio, B., Theunissen, P., Hervás‐Stubbs, S., Fortes, P., & Sarobe, P. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2303799 · Cited by 21
“116 They include not only CD8 epitopes, initially considered as major rejection antigens, but also CD4 epitopes, 117 which in addition to priming CD4 T cells with antitumor properties, may contribute to strengthen activation of CD8 responses.”
BackgroundIdentification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes
Tokita, S., Fusagawa, M., Matsumoto, S., Mariya, T., Umemoto, M., Hirohashi, Y., Hata, F., Saito, T., Kanaseki, T., & Torigoe, T. (2024) · Science Advances · doi:10.1126/sciadv.ado6491 · Cited by 19
Setting “cold” tumors on fire: Cancer therapy with live tumor-targeting bacteria
Manole, S., Nguyen, D.-H., Min, J.-J., Zhou, S., & Forbes, N. (2024) · Med · doi:10.1016/j.medj.2024.11.002 · Cited by 20
Metadata
- Authors
- Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- La Jolla Institute for Immunology (US)
- ORCID
- Venue
- Nature
- Published
- 2015-04-22
- Volume
- 520
- Issue
- 7549
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4838069
- OpenAlex
- W2079696222
- Cited by
- 1,243
- References
- 31
- Citations by year
- 2026: 64 · 2025: 93 · 2024: 114 · 2023: 120 · 2022: 124 · 2021: 149 · 2020: 144 · 2019: 101 · 2018: 99 · 2017: 99 · 2016: 95 · 2015: 38
- FWCI
- 54.27
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-06-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI107010)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- tumour mutations, MHC class II epitopes, neoantigens, CD4+ T cells, mRNA vaccines, personalized cancer immunotherapy, MHC class II binding prediction, tumor microenvironment, cytotoxic T lymphocytes, tumor rejection, exome sequencing, tumor immunogenicity
- MeSH terms
- Algorithms, Animals, Histocompatibility Antigens Class II, Computer Simulation, Disease Models, Animal, Female, Humans, Immunotherapy, Melanoma, Experimental, Mutation, CD4-Positive T-Lymphocytes, Survival Analysis, Sequence Analysis, DNA, Epitopes, T-Lymphocyte, Cancer Vaccines, Mice, Precision Medicine, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.